Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
AssigneeREMD Biotherapeutics, Inc.
InventorFrank J Calzone
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to combination therapy methods of treating a subject having cancer, comprising administering to the subject a) an effective amount of a pharmaceutical composition comprising a phosphatidylinositol 3-kinase (PI3K) pathway inhibitor, or a pharmaceutically acceptable salt thereof, and b) an effective amount of a pharmaceutical composition comprising a glucagon receptor antagonist.
Claims21
1-33. (canceled)
A method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a phosphatidylinositol 3-kinase (PI3K) pathway inhibitor, and a therapeutically effective amount of an isolated glucagon receptor (GCGR) antagonist.
Dependencies are inferred from the claim text.